Fate Therapeutics
25
4
5
7
Key Highlights
Risk & Performance
Pipeline Risk Assessment
Pipeline Risk Assessment
Based on historical performance
High Risk
Score: 100/100
48.0%
12 terminated/withdrawn out of 25 trials
36.8%
-49.7% vs industry average
0%
0 trials in Phase 3/4
43%
3 of 7 completed trials have results
Key Signals
Enrollment Performance
Analytics
Activity Timeline
Global Presence
Clinical Trials (25)
A Phase 2, Open-Label, Single-Arm Trial of FT819 in Participants With Lupus Nephritis
Role: lead
A Phase 1 Study of FT819 in B-cell Mediated Autoimmune Disease
Role: lead
First-in Cancer-Type Phase I Study of FT536 for Recurrent WHO Grade 4 Astrocytoma
Role: collaborator
FT819 in Subjects With B-cell Malignancies
Role: lead
FT836 With or Without Chemotherapy and/or Monoclonal Antibodies, in Participants With Advanced Solid Tumors
Role: lead
FT576 in Subjects With Multiple Myeloma
Role: lead
FT825/ONO-8250, an Off-the-Shelf, HER2 CAR-T, With or Without Monoclonal Antibodies in Advanced Solid Tumors
Role: lead
FT522 With Rituximab in Relapsed/Refractory B-Cell Lymphoma (FT522-101)
Role: lead
FT516 in Subjects With Advanced Hematologic Malignancies
Role: lead
FT596 as a Monotherapy and in Combination With Anti-CD20 Monoclonal Antibodies
Role: lead
FT516 in Combination With Monoclonal Antibodies in Advanced Solid Tumors
Role: lead
FT536 Monotherapy and in Combination With Monoclonal Antibodies in Advanced Solid Tumors
Role: lead
FT538 in Subjects With Advanced Hematologic Malignancies
Role: lead
FT538 in Combination With Monoclonal Antibodies in Advanced Solid Tumors
Role: lead
Long-term, Non-interventional, Observational Study Following Treatment With Fate Therapeutics FT500 Cellular Immunotherapy
Role: lead
FT596 in Combination With R-CHOP in Subjects With B-Cell Lymphoma
Role: lead
FT500 as Monotherapy and in Combination With Immune Checkpoint Inhibitors in Subjects With Advanced Solid Tumors
Role: lead
Study of ProTmune for Allogeneic HCT in Adult Patients With Hematologic Malignancies
Role: lead
Long-term Follow-Up Study Following Treatment With Fate Therapeutics' Engineered Cellular Immunotherapy
Role: lead
The PUMA Trial is a Trial of a Single ProHema Modulated-Cord Blood (CB) Unit as Part of a Double CB Transplant in Patients With Hematologic Malignancies.
Role: lead